Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies

Am J Hematol. 2020 Nov;95(11):E305-E308. doi: 10.1002/ajh.25949. Epub 2020 Aug 31.

Authors

Mark Y Jeng^{1

2}, Ritika Dutta^{1

2}, Irena T Tan¹, Tian Y Zhang^{1

2}, Gabriel N Mannis^{1

2}

Affiliations

¹ Division of Hematology, Department of Medicine, Stanford University, Stanford, California.
² Stanford School of Medicine, Stanford, California.

PMID: 32744731
DOI: 10.1002/ajh.25949

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Aged, 80 and over
Aniline Compounds / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Cyclopentanes / administration & dosage
Disease-Free Survival
Female
Glycine / administration & dosage
Glycine / analogs & derivatives
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / mortality*
Male
Pyrazines / administration & dosage
Pyridines / administration & dosage
Pyrimidines / administration & dosage
Retrospective Studies
Sulfonamides / administration & dosage
Survival Rate

Substances

Aniline Compounds
Antibodies, Monoclonal, Humanized
Bridged Bicyclo Compounds, Heterocyclic
Cyclopentanes
Pyrazines
Pyridines
Pyrimidines
Sulfonamides
gilteritinib
magrolimab
venetoclax
ivosidenib
pevonedistat
Glycine